The company said that recent study results show its Aventa Lymphoma test can provide actionable information that would typically be missed by FISH testing.

The company, which is in the process of being acquired, said that strong sales of its core molecular tests were offset by falling COVID-19 revenues and a decline in overall diagnostics sales in China.

Parent firm Siemens is considering reducing its ownership stake in Siemens Healthineers, which could mean the termination of existing financing agreements.

NEW YORK – Becton Dickinson reported before the opening of the market on Thursday that its fiscal fourth quarter revenues increased 8 percent year over year. For the quarter ended Sept. 30, 2025 BD ...

The firm said that growth in its immunodiagnostics business was offset by contraction in its molecular diagnostics, licensed technologies, and COVID-19 businesses.

Last week, readers were most interested in a story about Biodesix's journey as a publicly traded company and what lies ahead for it.

Of the 30 companies in the index, 21 firms saw their share prices rise month over month, while nine saw their stock prices decline.

Note: This story previously stated the xM test was licensed from Personalis, instead of the xM NeXT test. We regret the error. NEW YORK – With Medicare ...

These drugs, which are among the most common types of blood thinners, can interfere with traditional coagulation tests, producing unreliable results.